Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials

Animal models and observational human data indicate that complement, including C5a, pathogenically participates in ischemia reperfusion (IR) injury that manifests as delayed graft function (DGF) following deceased donor kidney transplantation. We report on the safety/efficacy of anti-C5 monoclonal a...

Täydet tiedot

Tallennettuna:

Bibliografiset tiedot
Päätekijät:	Bernd Schröppel, Enver Akalin, Mukta Baweja, Roy D. Bloom, Sander Florman, Michael J. Goldstein, Brandy Haydel, Donald E. Hricik, Sanjay Kulkarni, Matthew H. Levine, Anita Mehrotra, Anup Patel, Emilio D. Poggio, Lloyd E. Ratner, Ron Shapiro, Peter S. Heeger
Aineistotyyppi:	Artigo
Kieli:	englanti
Julkaistu:	2019
Linkit:	https://doi.org/10.1111/ajt.15580 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.15580
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Lisää ensimmäinen kommentti!

Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials

Samankaltaisia teoksia